SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
- Written by PR Newswire
 |
- SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand, with interim results expected by 2026
- Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI
- SK bioscience will expand its vaccine portfolio and secure global competitiveness by...
